Glencet Edvans coated tablets №28

Description

Glencet Edvans №28 Composition

active ingredients: montelukast, levocetirizine

1 coated tablet contains montelukast sodium equivalent to montelukast 10 mg levocetirizine dihydrochloride 5 mg

excipients: lactose, microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium croscarmellose, hydroxypropyl cellulose, magnesium stearate, yellow opadry 1ZV52204 (hypromellose, titanium dioxide (E 171), macrogol, iron oxide yellow (E172), polysorbate red (80 E172)).

Glencet Edvans №28 Dosage form

Film-coated tablets.

Basic physical and chemical properties:

yellow, round, biconvex film-coated tablets, smooth on both sides.

Glencet Edvans Pharmacological group

Respiratory system drugs.

ATX code R07A X.

Pharmacological properties

Pharmacodynamics.

Glenset EDVANCE contains a fixed combination of two active ingredients: montelukast and levocetirizine, therefore, the mechanisms of action of each component described below are characteristic of Glenset EDVANCE.

Montelukast blocks cysteinyl-leukotriene receptors in the respiratory tract, which was confirmed by its ability to prevent the development of bronchoconstriction caused by inhalation of LTD4 leukotrienes in patients with bronchial asthma. Even at doses as low as 5 mg, montelukast reliably blocks LTD4-induced bronchoconstriction.

Levocetirizine is the active R-enantiomer of cetirizine, an antihistamine. Its main effects are mediated by selective inhibition of H1 receptors. The antihistaminic effect of levocetirizine has been confirmed in various studies using experimental models in animals and humans. In the course of in vitro studies of binding to receptors, it turned out that the affinity of levocetirizine for human H1 receptors is 2 times higher than that of cetirizine (Ki = 3 nmol / L versus 6 nmol / L). The clinical significance of these findings is still unknown.

Indications

The fixed combination of montelukast and levocetirizine is intended to reduce symptoms associated with seasonal allergic rhinitis.

Contraindications

Hypersensitivity to any component of the drug.

Method of administration and dosage

For adults and children over 15 years of age, the recommended dose is 1 tablet per day, in the evening, regardless of the meal. The tablets are swallowed whole without chewing. The course of treatment is 14 days.